{"organizations": ["Intellia Therapeutics"], "uuid": "a8e8974eaa5c7940a26539f0ad0389b1e75d5d88", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.pharmamedtechbi.com", "main_image": "", "site_section": "http://feeds.feedburner.com/PharmaBiotechFinancing", "section_title": "Pharma/Biotech Financing From Elsevier Business Intelligence", "url": "https://www.pharmamedtechbi.com/deals/201530676?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d(%2540industries%253d%2522Pharmaceuticals%2522)%2520and%2520(%2540industries%253d%2522Biotechnology%2522)%2520and%2520(%2540dealtype%253d%2522Financing%2522)", "country": "IL", "title": "Intellia Therapeutics raises $70mm in Series B round", "performance_score": 0, "site": "pharmamedtechbi.com", "participants_count": 0, "title_full": "Intellia Therapeutics raises $70mm in Series B round", "spam_score": 0.0, "site_type": "news", "published": "2015-09-04T02:40:00.000+03:00", "replies_count": 0, "uuid": "a8e8974eaa5c7940a26539f0ad0389b1e75d5d88"}, "author": "", "url": "https://www.pharmamedtechbi.com/deals/201530676?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d(%2540industries%253d%2522Pharmaceuticals%2522)%2520and%2520(%2540industries%253d%2522Biotechnology%2522)%2520and%2520(%2540dealtype%253d%2522Financing%2522)", "ord_in_thread": 0, "title": "Intellia Therapeutics raises $70mm in Series B round", "locations": [], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "Intellia Therapeutics raises $70mm in Series B round Deal Date: Sep-01-2015 / Deal # 201530676 Executive Summary \nIntellia Therapeutics Inc. (gene editing utilizing CRISPR/Cas9 technology) raised $70mm in its Series B round led by OrbiMed HealthCare Fund Management, which takes a board seat. Fidelity Management & Research Co., Janus Capital Management, Foresite Capital, Sectoral Asset Management, EcoR1 Capital, and other investors participated, along with returning buyers Atlas Venture and partner Novartis AG . Leerink Partners was the placement agent.", "external_links": [], "published": "2015-09-04T02:40:00.000+03:00", "crawled": "2015-09-04T18:14:06.802+03:00", "highlightTitle": ""}